Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b

Neurology

Volumn 60, Issue 11, 2003, Pages 1849-1851

  Markovic Plese, S ^a,b   Bielekova, B ^a   Kadom, N ^a   Leist, T P ^a   Martin, R ^a   Frank, J A ^a   McFarland, H F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION;

EID: 0038115303     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000071218.34009.AF     Document Type: Article

References (10)

1. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
2. Stone LA, Fisher E, Cutter GR, et al. The predictive value of gadolinium enhancement for clinical status over a five- to ten-year period. Neurology [Suppl] 2002;209:P03.081.
3. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-869.
4. Cohen JA, Carter JL, Kinkel RP, Schwid SR. Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. J Neuroimmunol 1999;98:29-36.
5. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-1055.
6. Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998;18:1025-1030.
7. DeCarli C, Maisog J, Murphy DG, Teichberg D, Rapoport SI, Horwitz B. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr 1992;16:274-284.
8. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-25.
9. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
10. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-Analysis Group. Lancet 1999;353:964-969.